GW-441756 hydrochloride, TrKA receptor tyrosine kinase inhibitor

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Interferon beta (IFN-β) and TrkA are distinct but engaging biological targets. IFN-β is a cytokine approximately 20 kDa mainly expressed in fibroblasts monocytes and dendritic cells. It binds to IFNAR1 and IFNAR2 receptors leading to a signal transduction essential in antiviral defense. TrkA or tropomyosin receptor kinase A is a high-affinity receptor for nerve growth factor (NGF) with a molecular weight of about 140 kDa widely expressed in neurons. It plays an important role in the development and function of the nervous system.

Biological function summary

IFN-β initiates immune responses against viral infections contributing to inflammation regulation. It activates the JAK-STAT pathway and forms complexes with other cytokines to enhance antiviral activity. TrkA mediates survival and differentiation of neurons by signaling through NGF participating in neuronal cell differentiation and apoptosis prevention. This receptor operates in a receptor-ligand complex pivotal for neuronal signaling.

Pathways

Both IFN-β and TrkA involve critical signaling cascades. IFN-β engages predominantly through the JAK-STAT signaling pathway which is vital for immune response. TrkA participates in the MAPK/ERK and PI3K/Akt pathways connecting closely with proteins like RAF and AKT supporting survival and growth. These pathways highlight their roles in maintaining cellular health and functionality.

IFN-β shows relevance in multiple sclerosis due to its ability to modulate immune responses offering therapeutic avenues. TrkA's involvement with congenital insensitivity to pain with anhidrosis (CIPA) highlights its importance in neural health and pain perception. Both could link to other proteins; for instance reduced IFN-β can be observed in some viral infections while TrkA's interaction with NGF is an important factor in neuroregenerative disorders.